UNIVERSITE SIDI MOHAMMED BEN ABDELLAH

Their core work

Université Sidi Mohammed Ben Abdellah (USMBA) is a public research university in Fes, Morocco, with documented expertise spanning pharmaceutical sciences, biomedical chemistry, and regional cluster development. In their H2020 involvement, they contributed as a third-party mobility institution in MSCA-RISE projects, meaning they hosted and dispatched researchers for international exchanges rather than leading workpackages directly. Their most substantive scientific engagement was in nanomedicine — specifically the computational design and analysis of nanostructured drug carriers targeting intracellular parasites, combining molecular docking with pharmaceutical chemistry. They also participated in Mediterranean cluster-building initiatives, reflecting a broader institutional interest in cross-border research networking.

What they specialise in

How they've shifted over time

In their first H2020 engagement (2015), USMBA was anchored in regional economic and research network development — participating in a Mediterranean cluster-building project with little technical scientific focus. By 2017, their profile shifted sharply toward biomedical research: nanocarrier design, intracellular parasite biology, secretory pathway targeting, and computational drug screening. This pivot suggests that USMBA's pharmaceutical and chemistry faculties became the dominant face of their international research engagement during the H2020 period.

USMBA appears to be consolidating around pharmaceutical nanoscience and computational chemistry — the kind of profile that fits naturally into future health, neglected diseases, or advanced materials consortia needing a North African research partner with staff-exchange capacity.

How they like to work

USMBA has participated exclusively as a third party in MSCA-RISE projects — the EU mobility scheme for international researcher exchanges — meaning they function as a sending and hosting institution rather than a technical workpackage leader. They have never coordinated an H2020 project. With 14 distinct consortium partners across 10 countries from just 2 projects, their network is broad relative to their project count, which reflects the multi-partner structure typical of MSCA-RISE consortia rather than deep bilateral ties.

USMBA has connected with 14 unique partners across 10 countries through just 2 projects, a wide spread driven by the MSCA-RISE format which routinely involves 6-10 institutions per project. Their network is geographically diverse but shallow in depth — no evidence of recurring bilateral partnerships.

What sets them apart

USMBA is one of the few Moroccan universities with direct H2020 participation records, giving it a documented track record in EU-funded international research — a meaningful credential when building consortia that need a North African academic partner to qualify under MSCA-RISE third-country rules. Their combination of pharmaceutical chemistry and computational drug screening capacity, rare among Moroccan institutions in CORDIS data, makes them a specific rather than generic partner for health-focused or neglected tropical disease projects. For coordinators needing a credible Moroccan university with researcher exchange infrastructure already tested through EU projects, USMBA has a head start.

Highlights from their portfolio

• VAHVISTUS
  The most technically ambitious of the two projects, targeting smart nanostructures for intracellular parasite drug delivery — a niche intersection of nanomedicine, parasitology, and computational chemistry that signals real domain depth.
• CLUSDEV MED
  Demonstrates USMBA's early role as a Mediterranean regional node in cross-border cluster development, distinct from their later biomedical focus and showing institutional range.